Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Auerbach, Yancopoulos To Speak At Forbes Healthcare Summit
Puma Biotechnology
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology Surging
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotech punts near $300 million on Takeda discard
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology
Puma Biotechnology | Evaluate
Puma Biotechnology
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
